Evidence map›Paper›PMID 40614787›Full record

Trial reportInternational journal of radiation oncology, biology, physics2025

Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma.

Guangyuan Zhang, Xin Cai, Hong Cao, Zhan Yu, Weiwei Wang, Ying Xing, Jingfang Zhao, Qing Zhang, Bo Zhang, Fei Liang and 5 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Pancreatic cancer.Nature reviews. Disease primers · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guangyuan ZhangDepartment of Diagnostic Radiology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Xin CaiShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
Hong CaoDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China; Department of Radiation Oncology, Kunshan Hospital of Traditional Chinese Medicine, Jiangsu, China.
Zhan YuShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
Weiwei WangShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Ying XingShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Jingfang ZhaoShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Qing ZhangShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
Bo ZhangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Fei LiangDepartment of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.
Mansoor M AhmedDepartment of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Xiaodong WuExecutive Medical Physics Associates, Miami, Florida.
Chandan GuhaDepartment of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York. Electronic address: CGUHA@montefiore.org.
Guo-Liang JiangShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China. Electronic address: guoliang.jiang@sphic.org.cn.
Zheng WangShanghai Key Laboratory of Radiation Oncology, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China. Electronic address: zheng.wang@sphic.org.cn.

Funding

NCI NIH HHS HHSN261201500022C
6 · The paper itself

Abstract

purposeIn locally advanced pancreatic carcinoma (LAPC), combining chemotherapy with photon radiation therapy has not demonstrated survival benefits over chemotherapy alone. Conversely, carbon ion radiation therapy (CIRT) has shown encouraging outcomes from Japanese studies. The purpose of this trial was to assess the efficacy and toxicities of CIRT combined with chemotherapy in LAPC through a prospective phase 2 clinical trial. METHODS AND MATERIALS: Patients with histologically or cytologically confirmed pancreatic adenocarcinoma, locally advanced disease without gastrointestinal invasion, no distant metastasis, and who received induction chemotherapy were enrolled. The prescribed relative biological effectiveness-weighted dose of CIRT was 67.5 Gy in 15 fractions over 3 weeks, which was calculated by the local effect model version I. Chemotherapy was administered before and after CIRT. The primary endpoint was the 2-year locoregional progression-free survival rate.

resultsFrom 2018 to 2022, 49 patients (T

conclusionsAlthough the primary endpoint was not met, this prospective clinical trial of CIRT with chemotherapy demonstrated promising results with minimal toxicities in patients with LAPC. The findings strongly advocate for prospective randomized trials.

Indexed as

AdenocarcinomaChemoradiotherapyHeavy Ion RadiotherapyPancreatic NeoplasmsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleGemcitabineHumansInduction ChemotherapyMaleMiddle AgedProgression-Free SurvivalProspective StudiesGemcitabine

Identifiers

PMID40614787
PMCPMC12359858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.